Innovative Model Advances Fight Against Antimicrobial Resistance (AMR)
FiberCell Systems‘ hollow fiber infection model offers a precise method to study AMR, simulating human drug interactions effectively.
The FiberCell Systems Hollow Fiber Infection Model (HFIM) has emerged as a revolutionary tool in the study of antimicrobial pharmacodynamics and pharmacokinetics (PK/PD).
This model provides a dynamic and realistic simulation of in vivo drug effects, offering significant advantages over traditional methods. Here, we explore the key features and benefits of the HFIM in the context of antimicrobial research.
The HFIM utilizes hollow fiber bioreactor cartridges to create a two-compartment system that mimics human pharmacokinetics more accurately than previous models. These cartridges contain thousands of small tubular filters that allow drugs and small molecules to pass through while retaining larger entities like bacteria and cells. This setup enables precise control over drug concentration and exposure time, closely simulating the conditions found in human bodies.
The HFIM is particularly useful in studying the pharmacodynamics (PD) and pharmacokinetics (PK) of antibiotics. It allows researchers to examine how drugs interact with bacteria over time and at varying concentrations. This is crucial for understanding the efficacy of antibiotics and determining optimal dosing regimens. The model can simulate both the absorption and elimination kinetics of drugs, providing insights into how different dosing schedules can prevent the emergence of drug resistance.
The HFIM offers several advantages over traditional static and one-compartment models:
FiberCell Systems Hollow Fiber Infection Model represents a significant advancement in the study of antimicrobial PK/PD. By providing a more accurate simulation of human drug interactions, it enables researchers to develop more effective antibiotics and optimize dosing regimens. As the fight against antibiotic resistance continues, the HFIM will undoubtedly play a crucial role in shaping the future of antimicrobial therapy.
For more detailed information on PK/PD applications using the HFIM, please read the article, which you can download here.
We gladly support you by keeping you updated on our latest products and the developments around our services.